Menopause Lab Panel: Which Hormones to Track and When

Menopause is not a single event - it is a transition that unfolds over years. And while hot flashes and missed periods get most of the attention, the hormonal shifts of menopause affect virtually every system in your body: your brain, bones, heart, metabolism, sleep, and mood.

The right lab tests at the right time can help you understand where you are in this transition, identify emerging health risks, and make informed decisions about treatment - including whether hormone replacement therapy (HRT) might be right for you.

Understanding the Menopausal Transition

Perimenopause

The transition typically begins in your early to mid-40s (sometimes late 30s) and lasts an average of 4-8 years. During perimenopause:

• Estrogen fluctuates wildly - it can spike higher than in your 20s before eventually declining
• Progesterone drops first as cycles become anovulatory more frequently
• FSH begins to rise as the pituitary gland works harder to stimulate the ovaries
• Symptoms emerge: irregular periods, sleep disruption, mood changes, hot flashes

Menopause

Officially defined as 12 consecutive months without a period, the average age of menopause is 51. After this point:

• Estradiol drops by approximately 85%
• FSH rises and stays elevated (typically above 30 mIU/mL)
• Testosterone declines gradually (about 50% reduction by menopause)
• Health risks shift as protective hormonal effects diminish

The Essential Menopause Lab Panel

1. FSH (Follicle-Stimulating Hormone)

FSH is the classic marker used to assess menopausal status. As the ovaries produce less estrogen, the pituitary gland releases more FSH in an attempt to stimulate egg production.

• Premenopausal range: 3-10 mIU/mL (follicular phase)
• Perimenopausal: Often fluctuating, may be 10-25 mIU/mL
• Postmenopausal: Typically above 30 mIU/mL, often 40-100+ mIU/mL

Important caveat: During perimenopause, FSH can fluctuate dramatically from month to month. A single normal FSH does not rule out perimenopause. Serial testing over time provides a more accurate picture.

2. Estradiol (E2)

Estradiol is the primary and most potent form of estrogen. Tracking its decline helps gauge where you are in the transition and whether you might benefit from estrogen therapy.

• Premenopausal: 30-400 pg/mL (varies with cycle phase)
• Perimenopausal: Erratic, can be very high or very low
• Postmenopausal: Typically below 30 pg/mL, often below 20 pg/mL

3. Progesterone

Progesterone is often the first hormone to decline in the menopausal transition, as anovulatory cycles produce little to no progesterone. Low progesterone in the presence of fluctuating estrogen contributes to:

• Heavy, irregular periods
• Insomnia (progesterone promotes sleep)
• Anxiety and mood instability
• Estrogen dominance symptoms

4. Testosterone and SHBG

Testosterone often receives less attention during menopause, but its decline contributes significantly to:

• Low libido - one of the most common and distressing symptoms
• Fatigue and loss of motivation
• Reduced muscle mass and difficulty maintaining fitness
• Brain fog and decreased cognitive sharpness

SHBG typically increases after menopause (especially with oral HRT), which can further reduce available free testosterone.

5. Thyroid Panel

Thyroid disease becomes increasingly common as women age, and thyroid dysfunction symptoms closely mimic menopause symptoms - fatigue, weight gain, mood changes, brain fog, hair loss, and sleep disturbance. It is essential to rule out thyroid issues rather than attributing everything to menopause.

A complete thyroid panel should include:

• TSH - primary screening marker
• Free T4 - active thyroid hormone
• Free T3 - the most metabolically active thyroid hormone
• TPO antibodies - screens for Hashimoto thyroiditis (autoimmune thyroid disease, which peaks in prevalence around menopause)

6. Bone Health Markers

Estrogen plays a critical protective role in bone health. After menopause, bone loss accelerates significantly - women can lose up to 20% of their bone density in the first 5-7 years post-menopause.

Key markers include:

• Vitamin D (25-hydroxyvitamin D) - essential for calcium absorption; optimal levels are 40-60 ng/mL
• Calcium - baseline assessment
• Alkaline phosphatase - can indicate bone turnover
• Consider a DEXA scan (not a lab test but critical for bone density assessment)

7. Cardiovascular Risk Markers

Before menopause, estrogen provides significant cardiovascular protection. After menopause, women's cardiovascular risk increases to match that of men. Comprehensive lipid and metabolic testing becomes crucial:

• Complete lipid panel - total cholesterol, LDL, HDL, triglycerides
• Fasting insulin - insulin resistance increases dramatically after menopause
• Fasting glucose and HbA1c - screen for prediabetes and diabetes
• hsCRP (high-sensitivity C-reactive protein) - inflammatory marker linked to cardiovascular risk
• Apolipoprotein B (ApoB) - increasingly recognized as a superior predictor of cardiovascular risk compared to LDL alone

8. Additional Markers

• DHEA-S - adrenal hormone that declines with age; contributes to energy, libido, and well-being
• Cortisol - chronic stress can compound menopausal symptoms
• Vitamin B12 and folate - absorption can decline with age
• Iron studies (ferritin, TIBC) - relevant especially during perimenopause when heavy periods can cause depletion, and post-menopause when levels may rise

When to Test and How Often

During Perimenopause

• Baseline panel when symptoms first appear
• Repeat every 6-12 months to track progression
• Test on cycle day 2-5 if still menstruating (for FSH, estradiol, and other baseline hormones)
• For progesterone, test mid-luteal phase (7 days post-ovulation) if periods are still occurring

Post-Menopause

• Comprehensive panel within the first year of confirmed menopause
• Annual monitoring of metabolic, thyroid, and bone health markers
• Before and during HRT to guide dosing and monitor safety

The EllaDx Hormone & Longevity Panel provides a comprehensive snapshot of reproductive hormones, metabolic markers, and key health indicators that are essential during the menopausal transition. Combining it with the Thyroid Panel ensures no thyroid-related contributor is overlooked.

When HRT Might Help

Hormone replacement therapy has undergone a significant reassessment in recent years. Current evidence supports its use in appropriate candidates:

Who May Benefit

• Women with moderate to severe vasomotor symptoms (hot flashes, night sweats)
• Women experiencing significant quality-of-life impairment from menopausal symptoms
• Women at elevated risk of osteoporosis
• Women in early menopause (before age 45) or with premature ovarian insufficiency
• Women within 10 years of menopause onset or under age 60 (the "window of opportunity")

What the Evidence Shows

• HRT initiated in the early menopausal window may provide cardiovascular protection
• Transdermal estrogen (patches, gels) carries lower risk of blood clots compared to oral forms
• Micronized progesterone is preferred over synthetic progestins for most women
• Testosterone therapy for low libido is increasingly supported by evidence, though formulations specifically for women are limited

Lab Monitoring During HRT

Once on HRT, periodic monitoring helps ensure optimal dosing:

• Estradiol levels (target depends on route and goals)
• FSH (should decrease with adequate estrogen replacement)
• Complete metabolic and lipid panels
• Liver function tests (especially with oral formulations)

Tracking Your Transition

Menopause is not one-size-fits-all. Some women sail through with minimal symptoms; others find it profoundly disruptive. In either case, objective lab data empowers you to:

• Understand your symptoms in the context of measurable hormonal changes
• Identify emerging health risks (cardiovascular, metabolic, bone) early
• Make informed treatment decisions based on your unique hormonal profile
• Monitor the effectiveness of any interventions

Rather than guessing where you are in the menopausal transition, let the data guide you.

References

• Harlow, S. D., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10. *Journal of Clinical Endocrinology & Metabolism*, 97(4), 1159-1168.
• The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*, 29(7), 767-794.
• Randolph, J. F., et al. (2011). Change in follicle-stimulating hormone and estradiol across the menopausal transition. *Journal of Clinical Endocrinology & Metabolism*, 96(3), 746-754.
• Eastell, R., et al. (2016). Postmenopausal osteoporosis. *Nature Reviews Disease Primers*, 2, 16069.
• El Khoudary, S. R., et al. (2020). Menopause transition and cardiovascular disease risk. *Circulation Research*, 126(8), 1048-1063.
• Davis, S. R., et al. (2019). Global consensus position statement on the use of testosterone therapy for women. *Journal of Clinical Endocrinology & Metabolism*, 104(10), 4660-4666.